This week in psychedelic business news: Mindset Pharma files another patent for compounds with “perfect microdosing drug profile,” and Core One Labs is preparing to capitalize on functional mushroom market.
Research will focus on how various psychedelics can be used under proper supervision and guidance to treat severe depression, anxiety and PTSD.
Psychedelic Spotlight speaks to a Field Trip Health patient and a psychotherapist, whose experiences suggest ketamine can also treat anxiety among other mental health issues.
The pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9 billion market potential for such a treatment.
The psychedelic movement keeps on moving in the Pacific Northwest following Seattle’s decriminalization resolution passing earlier this year.
Mind Medicine Australia, a psychedelics advocacy organization that filed the application, says the country “lost a massive opportunity to be a leader in this field with this decision.”
Chief Medical Officer Guy Goodwin calls study “a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy.”
Journaling is a key practice for integrating psychedelic experiences into our everyday lives, but it’s also an effective analog tool that can help reclaim our lives from the strong pull of the digital world.
A travel journal company pivots from external trips to those unfolding in the mind, and the psychedelic community is embracing the one-of-a-kind integration workbook with open arms.
The comedian publicly expresses interest in the mental health treatment trend the same day as Paul Stamets’ massive microdosing study results were published.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.